Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC keeps 'outperform' on Burberry ahead of Q3 update

(Sharecast News) - RBC Capital Markets has reiterated its 'outperform' rating for Burberry ahead of a third-quarter trading update later this month, saying the stock could benefit from a valuation rerating if the British luxury brand delivers against consensus expectations. The broker has pencilled in retail revenues of £658m for the final three months of 2025 (Burberry's fiscal third quarter), representing 0% reported growth but 2% growth on a like-for-like basis.

RBC expects growth of 3% in Greater China, 2% across the Americas, 1% across Asia Pacific excluding China and a flat performance across the EMEIA division.

If Burberry can deliver on this, results "would be well received and would set the stock up strongly for early cal 2026", according to RBC.

"In our view, given the early phase of Burberry's turnaround, we believe absolute revenue estimates are equally important to growth rates, and we also expect a material improvement in the 'quality' of revenues given non recurrence of one-off inventory clearance activities in the prior-year period," RBC said.

"Key focus will likely be on current trading trends and extent of impact of new offer, price and brand positioning on traffic and other retail KPIs in our view."

The broker, however, has lowered its reported net income and earnings per share estimates for Burberry by 9% to reflect £50m of restructuring costs flagged at the interim results in November. Nevertheless, all adjusted forecasts have been left unchanged.

RBC left its 1,400p target price for the stock unchanged, though shares in the luxury company were down 2.4% at 1,327.50p by 0908 GMT.

Share this article

Related Sharecast Articles

RBC Capital Markets keeps Ashtead at 'outperform'
(Sharecast News) - RBC Capital Markets said first‑half trading at Ashtead Technology was solid, but slightly softer margins linked to ongoing Middle East and Asia disruptions prompted the broker to trim its estimates.
St James's Place tumbles as two more appointed representatives leave
(Sharecast News) - St James's Place tumbled on Thursday following a report that two more of its large appointed representatives have left the network.
Oxford Biomedica inks service deal with Plowshare Therapies
(Sharecast News) - Oxford Biomedica announced on Thursday that it has signed an agreement to provide process development and AAV GMP manufacturing services to Plowshare Therapies, supporting the biotechnology company's gene therapy programme for rare genetic diseases.
Berenberg lowers target price on Rio Tinto following Q2 update
(Sharecast News) - Analysts at Berenberg cut their price target on Rio Tinto from 8,200p to 8,100p on Thursday, saying higher‑than‑expected diesel costs in the Pilbara were likely to keep unit‑cost pressure elevated, while parts of the miner's Q2 production update pointed to downside risks in iron ore.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.